|
| Status |
Public on Jan 09, 2022 |
| Title |
Transcriptome profiles of liver biopsy tissues before and after cenicriviroc treatment in patients with non-alcoholic steatohepatitis |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Non-alcoholic steatohepatitis (NASH) is a sharpy emerging cause of liver fibrosis and cancer that leads to poor prognosis of the patients. A dual CCR2/CCR5 inhibitor, cenicriviroc, was tested in a phase IIb CENTAUR trial for its efficacy to reduce fibrosis.
|
| |
|
| Overall design |
Liver biopsy tissues were obtained before and after 1-year treatment with cenicriviroc 150mg once daily from fibrotic NASH patients who showed improvement (n=10) or no improvement (n=9) of fibrosis after the therapy, and genome-wide transcriptome profiles were generated by RNA-Seq.
|
| |
|
| Contributor(s) |
Zhu S, Qian T, Fujiwara N, Hoshida Y |
| Citation(s) |
34951993 |
| |
| Submission date |
May 24, 2021 |
| Last update date |
Apr 10, 2022 |
| Contact name |
Yujin Hoshida |
| Organization name |
University of Texas Southwestern Medical Center
|
| Street address |
5323 Harry Hines Blvd
|
| City |
Dallas |
| State/province |
TX |
| ZIP/Postal code |
75390 |
| Country |
USA |
| |
|
| Platforms (1) |
|
| Samples (38)
|
|
| This SubSeries is part of SuperSeries: |
| GSE85550 |
Molecular signature predictive of long-term liver fibrosis progression to inform anti-fibrotic drug development |
|
| Relations |
| BioProject |
PRJNA732406 |
| SRA |
SRP321163 |
Less...
More...